Skip to main content

Palo Santo raises $50 mln for largest-ever venture capital fund focused purely on psychedelic medicine

Venture capital fund Palo Santo is closing its oversubscribed debut fund with $50 million of commitments in what the two-year-old firm describes as the largest pure-play venture capital pool dedicated to developing FDA-approved psychedelic drugs, MarketWatch has learned.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.